LUNDSTEDT, TORBJORN,SEIFERT, ELISABETH,LEK, PER,BOMAN, ARNE
申请号：
NZ57678107
公开号：
NZ576781A
申请日:
2007.11.09
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
Disclosed are indole-phenyl amides as represented by the general formula (I), wherein R1 is an optionally substituted phenyl, benzyl or cyclohexyl group Z is a saturated or unsaturated, straight or branched chain acyclic hydrocarbon group having 1 to 5 carbon atoms R2 is selected from an amino, alkylamino, dialkylamino, or a guanidine group and wherein the remaining substituents are as defined herein. Representative compounds include those such as 3-amino-N-[(4-bromo-phenyl)-cyclohexylcarbamoylmethyl]-N-[2-(1H-indol-3-yl)-ethyl]-propionamide, 3-amino-N-[benzylcarbamoyl-(2-bromo-phenyl)-methyl]-N-[2-(1H-indol-3-yl)-ethyl]-propionamide hydrochloride and N-[(2-chloro-4-fluoro-phenyl)-(4-fluoro-phenylcarbamoyl)-methyl]-N-[2-(6-fluoro-1H-indol-3-yl)-ethyl]-3-guanidino-propionamide. Further disclosed is a pharmaceutical composition which comprises a compound as defined above, together with one or more pharmaceutically acceptable adjuvants, carriers, diluents or excipients for the treatment of inflammation, arthritic conditions, rheumatoid arthritis, osteoarthritis, psoriatic arthritis, mental disorders, or for inducing central nerve regeneration.
